Experimental Drug Firmonertinib Shows Promise in Lung Cancer with Uncommon EGFR Mutations

The oral targeted therapy firmonertinib demonstrated tumor shrinkage in a significant number of patients with advanced non-small cell lung cancer (NSCLC) driven by uncommon EGFR PACC mutations, according to results from the phase 1b FURTHER trial published in *Cancer Cell*. As a first treatment, firmonertinib shrank tumors in 43% to 68% of patients, depending on the dose, with a median progression-free survival of 11.1 to 16 months.